Skip to main content
Skip to "About government"
Language selection
Français
Government of Canada /
Gouvernement du Canada
Search
Search the website
Search
Menu
Main
Menu
Jobs and the workplace
Immigration and citizenship
Travel and tourism
Business and industry
Benefits
Health
Taxes
Environment and natural resources
National security and defence
Culture, history and sport
Policing, justice and emergencies
Transport and infrastructure
Canada and the world
Money and finances
Science and innovation
You are here:
Canada.ca
Library and Archives Canada
Services
Services for galleries, libraries, archives and museums (GLAMs)
Theses Canada
Item – Theses Canada
Page Content
Item – Theses Canada
OCLC number
1032995687
Link(s) to full text
LAC copy
LAC copy
Author
Fasih, Aisha.
Title
111In-labeled Nimotuzumab Modified with Nuclear Localization Sequences (NLS) : an Auger Electron-emitting Radiotherapeutic Agent for EGFR-overexpressing and Trastuzumab-resistant Breast Cancer.
Degree
MAST -- University of Toronto, 2011
Publisher
Toronto : University of Toronto, 2011.
Description
1 online resource
Notes
Includes bibliographical references.
Abstract
Objective: The cytotoxic property of anti-EGFR-1 monoclonal-antibody nimotuzumab modified with nuclear localization sequence and radiolabeled with 111In was evaluated in trastuzumab-resistant breast cancer cells. Methods: 111In-nimotuzumab-NLS was constructed and its immunoreactivity was determined. Cellular and nuclear uptake was evaluated by cell fractionation. Finally, the cytotoxicity of conjugates (111In-nimotuzumab/111In-nimotuzumab-NLS) was studied by clonogenic assays. Results: The immunoreactivity of 111In-nimotuzumab-NLS was conserved. 111In-nimotuzumab-NLS exhibited 2-fold higher nuclear translocation as compared to 111In-nimotuzumab in MDA-MB-468 cells. Nuclear importation of 111In-nimotuzumab-NLS in MDA-MB-468 cells was 4-fold and 6-fold higher than moderate and low EGFR expressing cell lines, respectively. Clonogenic survival (CS) for MDA-MB-468 cells showed 111In-nimotuzumab-NLS to be 10-folds and 60-folds more potent than 111In-nimotuzumab and nimotuzumab, respectively. Moderate killing for TrR1 and MDA-MB-231 was observed. 111In-hEGF showed significantly higher cytotoxicity and 2-fold higher [gamma]-H2AX foci integrated density/nuclear-area as compared to 111In-nimotuzumab-NLS. Preserved selectivity of 111In-nimotuzumab-NLS makes it an excellent drug for treating cancers.
Other link(s)
hdl.handle.net
tspace.library.utoronto.ca
Subject
Herceptin resistant breast cancer.
Auger eletron radiotherapy.
Nimotuzumab (mAb of EGFR)
Indium-111.
0572.
Date modified:
2022-09-01